TRex Bio, Inc. TRXB
10.32 USD +0.59 (+6.12%)
Regular-session close
10.32 0.00 0.00%
After hours · Nov 20, 4:00 PM ET
9.55 Day range 10.97
9.39 52-week range 15.50
- YTD
- -26.32%
- 1 year
- -26.32%
News
benzinga.com Trex Bio Q3 EPS $(10.06) Trex Bio (NASDAQ:TRXB) reported quarterly losses of $(10.06) per share . This is a 32.72 percent decrease over losses of $(7.58) per share from the same period last year.
globenewswire.com TRexBio Reports Third Quarter 2026 Financial Results and Recent Business Highlights Positive Phase 1a results for TRB-061 support proof of mechanism, with topline Phase 1b data in atopic dermatitis expected in mid-2027 TRB-071 advancing through IND-enabling studies, with Phase 1…benzinga.com Evercore ISI Group Initiates Coverage On Trex Bio with Outperform Rating, Announces Price Target of $28 Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Trex Bio (NASDAQ:TRXB) with a Outperform rating and announces Price Target of $28.
benzinga.com This X-Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday New coverage: Pony AI Overweight/$10, X-Energy Outperform/$17, TRex Bio Buy/$39, NuScale Underperform/$5.benzinga.com JP Morgan Initiates Coverage On Trex Bio with Overweight Rating, Announces Price Target of $20 JP Morgan analyst Brian Cheng initiates coverage on Trex Bio (NASDAQ:TRXB) with a Overweight rating and announces Price Target of $20.
benzinga.com Stifel Initiates Coverage On Trex Bio with Buy Rating, Announces Price Target of $39 Stifel analyst Alex Thompson initiates coverage on Trex Bio (NASDAQ:TRXB) with a Buy rating and announces Price Target of $39.
benzinga.com Wedbush Initiates Coverage On Trex Bio with Outperform Rating, Announces Price Target of $30 Wedbush analyst Martin Fan initiates coverage on Trex Bio (NASDAQ:TRXB) with a Outperform rating and announces Price Target of $30.
globenewswire.com TRexBio Announces Closing of Initial Public Offering SOUTH SAN FRANCISCO, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and…
globenewswire.com TRexBio Announces Pricing of Initial Public Offering SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and…
